North Dakota Medicaid and tirzepatide
Zepbound for weight loss: no. Criteria cover moderate to severe obstructive sleep apnea with obesity and a failed CPAP trial. Zepbound is non-preferred. Mounjaro for weight loss: no. Mounjaro is listed for reduction of major heart events as non-preferred, after a failed semaglutide trial. It is not on the obesity list.; for type 2 diabetes North Dakota Medicaid must cover it. Read from North Dakota Department of Health and Human Services, Medical Services Division documents Nov 6, 2026.
In 2025 North Dakota Medicaid paid for 67 tirzepatide prescriptions (Mounjaro), 1.1% of its GLP-1 prescriptions and 51st of the 50 states and DC. It reimbursed $70,880 before rebates, $1,058 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 67 | $70,880 | $1,058 |
North Dakota plans and prescribing rules
NDPERS group health plan. North Dakota's NDPERS says GLP-1s are only available for the treatment of diabetes, not for weight loss, per its 2026 health insurance RFP answers and its October 2025 board materials.
Blue Cross Blue Shield of North Dakota. Blue Cross Blue Shield of North Dakota removed weight-loss drug coverage, GLP-1s included, from fully insured non-grandfathered large group plans starting January 1, 2026 at plan anniversary. Self-funded employers choose whether to include these drugs.
Tirzepatide in the states around North Dakota
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| North Dakota | 15 | $69/moWellmedr | 67 | Medicaid Zepbound: No |
| Minnesota | 17 | $69/moWellmedr | 49,251 | Medicaid Zepbound: Yes |
| Montana | 17 | $69/moWellmedr | 2,904 | Medicaid Zepbound: No |
| South Dakota | 17 | $69/moWellmedr | 7,486 | Medicaid Zepbound: No |



